Advertisement

pp 1-4 | Cite as

A Third Case of Glycogen Storage Disease IB and Giant Cell Tumour of the Mandible: A Disease Association or Iatrogenic Complication of Therapy

  • Raajiv Prasad
  • Jane Estrella
  • John Christodoulou
  • Geoffrey McKellar
  • Michel C. Tchan
Research Report
Part of the JIMD Reports book series

Abstract

We report the third case of Glycogen Storage Disease type 1b (GSD 1b) with Giant Cell Tumour (GCT) of the mandible, associated with Granulocyte Colony Stimulating Factor (G-CSF) use. G-CSF in GSD 1b is indicated for persistent neutropaenia, sepsis, inflammatory bowel disease and severe diarrhoea. Our patient was 12 years old at GCT diagnosis and had been treated with G-CSF from 5 years of age. He underwent therapy with interferon followed by local resection which was successful in initial control of the disease. Histology demonstrated spindle shaped stromal cells together with numerous interspersed multinuclear osteoclastic giant cells. G-CSF has been hypothesized to induce osteoclastic differentiation and thus may be involved in the pathogenesis of GCT formation. At age 19 years he required a repeat operation for local recurrence. He currently continues on G-CSF and was commenced on denosumab for control of the GCT with no recurrence to date. A cause and effect relationship between G-CSF therapy and the development of GCT in GSD type 1b remains to be established.

Keywords

G-CSF Giant cell tumour of the mandible Glycogen storage disorder SLC37A4 

References

  1. Amanatullah DF, Clark TR, Lopez MJ, Borys D, Tamurian RM (2014) Giant cell tumor of bone. Orthopedics 37:112–120CrossRefPubMedGoogle Scholar
  2. Amaral FR, Carvalho VM, Fraga MG, Amaral TM, Gomes CC, Gomez RS (2009) Oral giant cell granuloma in a patient with glycogen storage disease. Open Dent J 3:144–146CrossRefPubMedPubMedCentralGoogle Scholar
  3. Barrett AP, Buckley DJ, Katelaris CH (1990) Oral complications in type 1B glycogen storage disease. Oral Surg Oral Med Oral Pathol 69:174–176CrossRefPubMedGoogle Scholar
  4. Burda P, Hochuli M (2015) Hepatic glycogen storage disorders: what have we learned in recent years? Curr Opin Clin Nutr Metab Care 18:415–421CrossRefPubMedGoogle Scholar
  5. Chou JY, Jun HS, Mansfield BC (2015) Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes. J Inherit Metab Dis 38:511–519CrossRefPubMedGoogle Scholar
  6. Kishnani PS, Austin SL, Abdenur JE et al (2014) Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med 16:e1PubMedGoogle Scholar
  7. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL (2005) M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 115:3418–3427CrossRefPubMedPubMedCentralGoogle Scholar
  8. Liu B, Yu SF, Li TJ (2003) Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. J Oral Pathol Med 32:367–375CrossRefPubMedGoogle Scholar
  9. Mortellaro C, Garagiola U, Carbone V, Cerutti F, Marci V, Bonda PL (2005) Unusual oral manifestations and evolution in glycogen storage disease type Ib. J Craniofac Surg 16:45–52CrossRefPubMedGoogle Scholar
  10. O’Connell JE, Bowe C, Murphy C, Toner M, Kearns GJ (2015) Aggressive giant cell lesion of the jaws: a review of management options and report of a mandibular lesion treated with denosumab. Oral Surg Oral Med Oral Pathol Oral Radiol 120:e191–e198CrossRefPubMedGoogle Scholar
  11. Pinsk M, Burzynski J, Yhap M, Fraser RB, Cummings B, Ste-Marie M (2002) Acute myelogenous leukemia and glycogen storage disease 1b. J Pediatr Hematol Oncol 24:756–758CrossRefPubMedGoogle Scholar
  12. Schipperus MR, Sonneveld P, Lindemans J et al (1990) The combined effects of Il-3, GM-CSF and G-CSF on the in vitro growth of myelodysplastic myeloid progenitor cells. Leuk Res 14:1019–1025CrossRefPubMedGoogle Scholar
  13. Schroeder T, Hildebrandt B, Mayatepek E, Germing U, Haas R (2008) A patient with glycogen storage disease type Ib presenting with acute myeloid leukemia (AML) bearing monosomy 7 and translocation t(3;8)(q26;q24) after 14 years of treatment with granulocyte colony-stimulating factor (G-CSF): a case report. J Med Case Rep 2:319CrossRefPubMedPubMedCentralGoogle Scholar
  14. Simmons PS, Smithson WA, Gronert GA, Haymond MW (1984) Acute myelogenous leukemia and malignant hyperthermia in a patient with type 1b glycogen storage disease. J Pediatr 105:428–431CrossRefPubMedGoogle Scholar
  15. Visser G, Rake JP, Labrune P et al (2002) Consensus guidelines for management of glycogen storage disease type 1b – European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 161(Suppl 1):S120–S123PubMedGoogle Scholar

Copyright information

© Society for the Study of Inborn Errors of Metabolism (SSIEM) 2017

Authors and Affiliations

  • Raajiv Prasad
    • 1
  • Jane Estrella
    • 2
    • 3
  • John Christodoulou
    • 4
    • 5
  • Geoffrey McKellar
    • 6
  • Michel C. Tchan
    • 7
    • 8
  1. 1.Hobart Clinical School, University of TasmaniaHobartAustralia
  2. 2.Western Sydney University Clinical School, Campbelltown CampusCampbelltownAustralia
  3. 3.Department of EndocrinologyCampbelltown HospitalCampbelltownAustralia
  4. 4.Neurodevelopmental Genomics Research GroupMurdoch Children’s Research InstituteParkvilleAustralia
  5. 5.Department of Paediatrics, Melbourne Medical SchoolUniversity of MelbourneMelbourneAustralia
  6. 6.Department of Oral and Maxillofacial SurgeryWestmead HospitalWestmeadAustralia
  7. 7.Department of Genetic MedicineWestmead HospitalWestmeadAustralia
  8. 8.Sydney Medical School, University of SydneyCamperdownAustralia

Personalised recommendations